Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBR-101 (fremanezumab) in high frequency episodic migraine
NCT02025556Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fremanezumab in migraine (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Mean Change From Baseline in the Monthly Migraine Days at 12 weeks, Number of Participants With at Least One Adverse Event at 12 weeks and 1 more. Started Jan 2014; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02025556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025556.